Kari Grønås

Director/Board Member chez SPAGO NANOMEDICAL AB Fortune : 4 905 $ au 31/03/2024

Profil

Kari Grønås currently works at Spago Nanomedical AB, as Independent Director from 2018, Ultimovacs ASA, as Director from 2019, K & K AS, as Managing Director & Director from 2012, Norwegian Cancer Society, as Director, and Arxx Therapeutics AS, as Director.
Ms. Grønås also formerly worked at Norwegian Pharmaceutical Society, as Chairman, Oncopeptides AB, as Director, Lytix Biopharma AS, as Director, BerGenBio ASA, as Independent Non-Executive Director from 2016 to 2019, SoftOx Solutions AS, as Non-Executive Director, and Algeta ASA, as Senior Vice President-Operations.
Ms. Grønås received her graduate degree from the University of Oslo.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
ULTIMOVACS AS 0,02%	31/12/2022	6 640 ( 0,02% )	4 905 $	31/03/2024

Postes actifs de Kari Grønås

Sociétés	Poste	Début
SPAGO NANOMEDICAL AB	Director/Board Member	01/01/2018
ULTIMOVACS ASA	Director/Board Member	01/01/2019
K & K AS	Chief Executive Officer	21/05/2012
Norwegian Cancer Society	Director/Board Member	-
Arxx Therapeutics AS	Director/Board Member	-

Anciens postes connus de Kari Grønås

Sociétés	Poste	Fin
BERGENBIO ASA	Director/Board Member	13/03/2019
ONCOPEPTIDES AB	Director/Board Member	-
SOFTOX SOLUTIONS	Director/Board Member	-
Norwegian Pharmaceutical Society	Chairman	-
░░░░░░ ░░░	░░░░░ ░░░░░░░░░ ░░░░░░░	-

Formation de Kari Grønås

University of Oslo

Graduate Degree